Good morning.
My name is Jonathan Bagger and I am the director of TRIUMF, the national laboratory for particle and nuclear physics and accelerator-based science.
I am accompanied today by Mr. Sean Lee, who is responsible for external relations at TRIUMF.
I thank the members of the Standing Committee on Natural Resources for having invited me today.
Let me start by saying a few words about TRIUMF. We are a large science research facility, located in Vancouver, that is owned and operated by 19 universities stretching across Canada. We employ approximately 500 staff and students, making our laboratory one of the largest of its kind in Canada. We are also an interdisciplinary laboratory, with world-class programs in the physical and life sciences, quantum materials, and accelerator science. We have a deep-seated commitment to the commercialization of our technologies.
Ultimately, what we do can be stated quite simply. TRIUMF is a factory for discovery and innovation that advances research for science, medicine, and business. From the abstract to the applied, we solve problems for the benefit of Canadians.
This morning I would like to highlight Canadian expertise in accelerator science, explain how this translates into a competitive advantage for medical isotopes, and argue that Canada risks losing this advantage unless the federal government assumes active stewardship of this field.
As you well know, Canada has a storied history as a world leader in nuclear technology. However, Canada's expertise extends far beyond nuclear reactors. Since TRIUMF's founding nearly 50 years ago, Canada has been a global leader in the development of particle accelerators. Such accelerators are at the heart of everything we do at TRIUMF. Our laboratory is home to the world's largest cyclotron, as well as a new superconducting linear accelerator that will open opportunities for generations to come. Accelerators are used in fundamental science and also for a host of applications in advanced materials, clean technologies, electronics and aerospace, defence and security, data sciences, and natural resources exploration.
Particle accelerators also have a proven capability in life-saving medical isotopes. TRIUMF is a world leader in this endeavour, and this is the area on which I will focus this morning. TRIUMF's history with medical isotopes dates back decades. Together with Nordion, we produce more than two million doses of medical isotopes per year that are shipped to patients in over a dozen countries. It is an enormously successful public-private partnership, one of which Canada should be proud. Beyond this, TRIUMF helped pioneer PET imaging in Canada and today supports the diagnosis and treatment of diseases ranging from cancer to Parkinson's. We are, in fact, the only proton therapy treatment centre in Canada.
TRIUMF is the hub of an innovation cluster that includes clinical and academic partners, with an industrial base that has commercialized our technology and made it available to the world. The value of this cluster came to light in 2007 and 2009, following NRU shutdowns that resulted in global shortages of technetium, a critical medical isotope used in 80% of nuclear medicine scans. Facing this crisis, the federal government launched the ITAP program to develop alternatives to the reactor-based production of technetium.
A TRIUMF-led consortium rose to the challenge and developed a new technology that produces technetium using medical accelerators. Our solution is environmentally friendly and enables locally sourced production of technetium, ensuring isotope independence for any region or country that adopts it. TRIUMF's technology was recognized with NSERC's prestigious Brockhouse prize, presented by Governor General David Johnston in February 2015. It is currently in the final stages of Health Canada review, and full regulatory approval is expected in late 2017. TRIUMF's innovative technology is now licensed to a spinoff company, and there is growing interest from international markets.
All this achievement and early promise, however, might well come to naught. The reality is that TRIUMF's technology is struggling to take root because of a lack of government leadership on the medical isotope file. With the end of ITAP, and the cessation of isotope production at the NRU, NRCan has decided to close its file. No one else has stepped up to claim ownership, so the isotope file is an orphan.
This brings us to where we are now—at a critical crossroads. With strong stewardship from the federal government, Canada is well positioned to extend its lead in medical isotope technologies, but without such a commitment, Canada will miss the opportunity, risk another supply shortage, and lose the capacity and expertise we have assembled over decades.
Our proposed institute for advanced medical isotopes, or IAMI, will ensure that Canada stays at the cutting edge. Details about IAMI are contained in the brief that we submitted to the clerk. Championed by TRIUMF, the BC Cancer Agency, the University of British Columbia, and Simon Fraser University, IAMI is a facility that will strengthen Canada's capacity in nuclear medicine for both research and clinical use.
On the one hand, IAMI will provide a reliable supply of the life-saving technetium isotope. It will demonstrate TRIUMF's technetium technology and serve as a model that can be replicated across Canada and around the world. On the other hand, IAMI will future-proof Canada's medical isotope R and D. Leveraging the experience and the unique capabilities of TRIUMF, IAMI will produce next-generation isotopes, many of which have tremendous therapeutic potential for treating cancer and other diseases. In fact, TRIUMF is one of the few places in the world capable of producing large quantities of these therapeutic isotopes. IAMI will provide the necessary infrastructure to ensure that Canada remains at the centre of this fast-moving and innovative field.
Despite this great promise, IAMI and initiatives like it are falling through the cracks. TRIUMF is working to build Canada's future in nuclear medicine, but we cannot do it alone. The federal government, and parliamentarians like you, must decide whether Canada should continue to play a leadership role in this sector. The benefits are many, but without clarity, commitment, and leadership from the federal government, we risk letting our position slip away.
Canada's work in nuclear research and development generates many advantages. We encourage the committee to take into account the contributions we can make to nuclear medicine today and in the years to come.
I'd be happy to answer questions when you have the time.
Thank you.